What blood tests are used to diagnose carcinoid tumors?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Blood Tests for Diagnosing Carcinoid Tumors

Chromogranin A (CgA) and 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA) are the primary blood tests used to diagnose carcinoid tumors, with CgA serving as a general marker for all neuroendocrine tumors and 5-HIAA specifically for carcinoid syndrome. 1, 2

Primary Diagnostic Tests

General Markers

  • Chromogranin A (CgA):
    • First-line blood test for all neuroendocrine tumors
    • Produced in large quantities by neuroendocrine cells
    • Elevated in most carcinoid cases, particularly with metastatic disease
    • Can be used for both diagnosis and monitoring disease progression 1, 2

Syndrome-Specific Tests

  • 24-hour urinary 5-HIAA:
    • Specific for carcinoid syndrome
    • Metabolite of serotonin produced by carcinoid tumors
    • Varies by tumor location:
      • Midgut carcinoids: Usually elevated (70% of patients)
      • Foregut carcinoids: Sometimes elevated
      • Hindgut carcinoids: Typically not elevated 1, 2

Additional Biochemical Tests

Tumor-Specific Markers

  • Tachykinins (neurokinin A and B):

    • Elevated in midgut carcinoids 1
  • Whole blood serotonin:

    • Can be useful but less commonly used clinically
    • Levels vary with time of day and meals
    • May remain elevated despite treatment 3

General Screening Tests

  • Thyroid function tests (TFTs)
  • Parathyroid hormone (PTH)
  • Serum calcium
  • Calcitonin
  • Prolactin
  • Alpha-fetoprotein (AFP)
  • Carcinoembryonic antigen (CEA)
  • Beta-human chorionic gonadotropin (β-HCG) 1

Collection and Testing Considerations

For 5-HIAA Testing

  • Potential false positives: Avoid these foods/medications 24 hours before collection:

    • Foods: Bananas, avocados, aubergines, pineapples, plums, walnuts
    • Medications: Paracetamol, fluorouracil, methysergide, naproxen, caffeine 1
  • Potential false negatives from:

    • Levodopa, aspirin, ACTH, methyldopa, phenothiazines 1

For CgA Testing

  • Blood sample collection:
    • 10 ml standard heparin bottle with trasylol (aprotinin)
    • Must be spun immediately before freezing
    • Send to specialized reference laboratories 1

Testing Algorithm

  1. Initial suspicion of carcinoid tumor:

    • Order baseline CgA and 24-hour urinary 5-HIAA 1, 2
  2. If carcinoid syndrome suspected:

    • Add specific tests based on suspected syndrome (see table below)
  3. If results are equivocal but suspicion remains high:

    • Consider imaging studies (multiphase CT/MRI and somatostatin receptor scintigraphy) 2
  4. For monitoring after diagnosis:

    • Measure CgA and 5-HIAA every 3-6 months 2

Syndrome-Specific Testing Guide

Tumor Location Primary Test Expected Result
Foregut carcinoid 24h urinary 5-HIAA Sometimes raised
Midgut carcinoid 24h urinary 5-HIAA + Tachykinins Usually raised (70%)
Hindgut carcinoid CgA (general markers) 5-HIAA not raised

Important Caveats

  • Diagnostic accuracy: No single test is 100% sensitive or specific; combining biochemical testing with imaging yields the best results 4
  • Platelet saturation: Blood serotonin may remain elevated despite treatment due to platelet saturation 3
  • Treatment effects: Somatostatin analogs can affect test results, with treated patients showing different biomarker patterns than untreated patients 5
  • Definitive diagnosis: While blood tests are valuable, histological confirmation remains the gold standard 1

Remember that a multidisciplinary approach involving specialists in gastroenterology, oncology, endocrinology, radiology, nuclear medicine, and pathology is essential for proper diagnosis and management of carcinoid tumors 1, 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.